Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Upstream Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Upstream Bio, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-343417
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | $773 | $937 | $1,807 | $1,503 |
| Operating expenses: | ||||
| Research and development | 36,089 | 37,865 | 72,654 | 63,662 |
| General and administrative | 7,052 | 7,419 | 15,136 | 14,201 |
| Total operating expenses | 43,141 | 45,284 | 87,790 | 77,863 |
| Loss from operations | (42,368) | (44,347) | (85,983) | (76,360) |
| Other income (expense): | ||||
| Interest income | 2,659 | 4,431 | 5,713 | 9,174 |
Item 1. Financial Statements.
FAQ
- What is Upstream Bio, Inc.'s R&D?
- Upstream Bio, Inc. (UPB) reported R&D of $36.09M in Q2 2026.
- How has Upstream Bio, Inc.'s R&D changed year-over-year?
- Upstream Bio, Inc.'s R&D decreased by 4.7% year-over-year, from $37.87M to $36.09M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Upstream Bio, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude